Algorithm for external treatment of dermatoses of mixed etiology
- Authors: Belousova TA1, Goryachkina MV1, BELOUSOVA TA1, GORYACHKINA MV1
-
Affiliations:
- Issue: Vol 87, No 5 (2011)
- Pages: 138-144
- Section: Articles
- Submitted: 11.03.2020
- Published: 15.10.2011
- URL: https://vestnikdv.ru/jour/article/view/1084
- DOI: https://doi.org/10.25208/vdv1084
- ID: 1084
Cite item
Full Text
Abstract
There has been an increase in the number of dermatology patients suffering from several concomitant skin diseases
of different etiology for the past decade. A special term - dermatoses of mixed etiology (DME) - was suggested to
describe this group of diseases. According to the authors, long-term uninterrupted treatment with one-component topical
drugs or unreasonable administration of three-component combination agents is the most frequent reason for DME.
The authors describe their positive experience of administering Travocort as a part of DME treatment. The effect of the
drug was observed as early as on the second day of its administration: there was an active regression of hyperemia,
edemas and skin oozing lesions in the foci. Itching and stinging disappeared almost completely, which also alleviated
the patients condition. On Days 3-4, no formation of new vesicles was observed, there were no oozing lesions, and
erosion cuticularization began on an active basis. Therefore, Travocort is a highly efficient drug for treatment of infectious
dermatoses complicated with eczematization as well as chronic inflammatory diseases exacerbated by a concomitant
fungous and bacterial infection.
of different etiology for the past decade. A special term - dermatoses of mixed etiology (DME) - was suggested to
describe this group of diseases. According to the authors, long-term uninterrupted treatment with one-component topical
drugs or unreasonable administration of three-component combination agents is the most frequent reason for DME.
The authors describe their positive experience of administering Travocort as a part of DME treatment. The effect of the
drug was observed as early as on the second day of its administration: there was an active regression of hyperemia,
edemas and skin oozing lesions in the foci. Itching and stinging disappeared almost completely, which also alleviated
the patients condition. On Days 3-4, no formation of new vesicles was observed, there were no oozing lesions, and
erosion cuticularization began on an active basis. Therefore, Travocort is a highly efficient drug for treatment of infectious
dermatoses complicated with eczematization as well as chronic inflammatory diseases exacerbated by a concomitant
fungous and bacterial infection.
References
- Котрехова Л.П. Диагностика и рациональная терапия дерматозов сочетанной этиологии. Consilium medicum (приложение «Дерматология»), 2010; 4: 6-11.
- Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycosis, 2008; 51: Suppl 4; 2-15.
- Рукавишникова В.М. Микозы стоп. «Эликс Ком», Москва, 2003.
- Ю.А. Белькова, Л.С. Страчунский, О.И. Кречикова, Н.В. Иванчик, А.В. Дехнич. Сравнительная эффективность 0,75% мази хлорамфеникола и 2% мази мупироцина при лечении в амбулаторных условиях взрослых пациентов с инфекциями кожи и мягких тканей. Клин. микр. и антимикроб. химиотерап. 2007. Т. 9, № 1. С. 57-66.
- Третьякова Н.Н. Дифференциальная диагностика и принципы терапии ладонно-подошвенного псориаза. Клин. дерматол. и венерол., 2010; 5: 113-119.
- Лукьянова Е.Н., Корсунская И.М., Невозинская З.А. и др. Особенности терапии кератодермий, осложненных микозом. Вестн. дерматол. и венерол. 2011; 2: 93-95.
- Edmondson S., Thumiger S., Werther G. et al. The role of the growth hormone and insulin-like growth factor system. Endocrine Reviews 2003; 24 (6): 737-64.
- Потекаев Н.Н., Шерина Т.Ф. К вопросу об ассоциации дерматозов и микозов кожи. Рос. журн. кож. и вен. бол. 2004. № 6. С. 55-57.
- Васильева Н.В., Разнатовский К.И., Котрехова Л.П. и др. Мониторирование чувствительности клинически значимых микромицетов к изоконазолу (субстанции кремов травоген, травокорт), оценка его эффективности и безопасности в лечении больных микозами кожи. Пробл. мед. микол. 2007; 2: 19-21.
- Босак И.А., Котрехова Л.П. Действие изоконазола в отношении избранных бактерий. Пробл. мед. микол. 2010; 12: 4: 49-51.
- Машкилейсон А.Л., Гомберг М.А., Ладыгина Н.В. и др. Клиническая эффективность противогрибковых препаратов травогена, травокорта, гино-травогена в практике дерматовенеролога и гинеколога. ЗППП, 1997; 2: 63-66.
- Dogan B., Karabudak O. Treatment of candidal intertrigo with a topical combination of isoconazole nitrate and diflucortolone valerate. Mycoses 2008; 4: 42-43.
- Havlickova B., Friedrich M. The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses. Mycoses 2008; Sep: 51: Suppl. 4: 16-26.
- Молочков А.В., Шульман Е.И., Устинов М.В. и др. Результаты наблюдательного исследования трамплин по оценке эффективности, безопасности и переносимости крема травоген и крема травокорт в Москве. Вестн. дер- матол. и венерол. 2010; 2: 101-105.